BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9007221)

  • 1. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients.
    Molineux G; Hartley C; McElroy P; McCrea C; Kerzic P; McNiece I
    Stem Cells; 1997; 15(1):43-9. PubMed ID: 9007221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice.
    Honda K; Takenaka K; Shinagawa K; Ishimaru F; Ikeda K; Niiya K; Harada M
    Bone Marrow Transplant; 2001 Aug; 28(4):329-34. PubMed ID: 11571503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
    Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
    Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression.
    Coleman D; Fairchild D; Schindler-Horvat J; Munyakazi L; Neumann TA
    Toxicol Sci; 1998 Sep; 45(1):77-87. PubMed ID: 9848114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
    Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
    Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
    Bolwell B; Vredenburgh J; Overmoyer B; Gilbert C; Chap L; Menchaca DM; Cruickshank S; Glaspy J
    Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
    Molineux G; Hartley C; McElroy P; McCrea C; McNiece IK
    Blood; 1996 Jul; 88(1):366-76. PubMed ID: 8704197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
    Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
    Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
    Farese AM; MacVittie TJ; Roskos L; Stead RB
    Stem Cells; 2003; 21(1):79-89. PubMed ID: 12529554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous intravenous administration of rmGM-CSF enhances immune as well as hematopoietic reconstitution following syngeneic bone marrow transplantation in mice.
    Naparstek E; Ohana M; Greenberger JS; Slavin S
    Exp Hematol; 1993 Jan; 21(1):131-7. PubMed ID: 8417949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
    Geissler K; Yin JA; Ganser A; Sanz MA; Szer J; Raghavachar A; Hoelzer D; Martinez C; Taylor K; Kanz L; To LB; Archimbaud E
    Ann Hematol; 2003 Nov; 82(11):677-83. PubMed ID: 14530872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
    Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of in vivo administration of IL-3 and IL-6, alone and in combination with G-CSF, GM-CSF or IL-1, on haematopoiesis, graft-versus-host disease and survival after murine haematopoietic stem cell transplantation.
    Atkinson K; Vos B; Kang-Er Z; Guiffre A; Seymour R; Gillis S
    Cytokines Mol Ther; 1995 Mar; 1(1):47-55. PubMed ID: 9384663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin: biology and clinical potentials.
    Miyazaki H; Kato T
    Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
    Shibuya K; Akahori H; Takahashi K; Tahara E; Kato T; Miyazaki H
    Blood; 1998 Jan; 91(1):37-45. PubMed ID: 9414267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation.
    Molineux G; Hartley CA; McElroy P; McCrea C; McNiece IK
    Blood; 1996 Aug; 88(4):1509-14. PubMed ID: 8695873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
    Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia.
    Farese AM; Hunt P; Grab LB; MacVittie TJ
    J Clin Invest; 1996 May; 97(9):2145-51. PubMed ID: 8621805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
    Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
    Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells.
    Neelis KJ; Dubbelman YD; Qingliang L; Thomas GR; Eaton DL; Wagemaker G
    Exp Hematol; 1997 Sep; 25(10):1084-93. PubMed ID: 9293906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.